Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/490"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value | |
| ?:content |
"route of admininistration: oral
study duration: 5 days
population: 16 healthy subjects (12 male, 4 female) from the UK; 14 Caucasian, 2 of African ancestry
tested for known CYP450 polymorphisms?
Yes -- CYP2D6 and CYP2C19 genotyping -- 1 CYP2D6 poor metabolizer
ages: 18-45
description:
SUBJECTS: 16 healthy subjects (18-45 years; 12 male and four female (14 Caucasian and two black subjects) in the cimetidine study were recruited in the UK. CYP2D6 and CYP2C19 [genotyping] were determined according to standard methods. The results were only used to aid interpretation of the pharmacokinetic results.
STUDY DESIGN: Sixteen subjects were administered cimetidine (400 mg twice daily) or placebo for 5 days. On the morning of day 4, a single dose of 20 mg escitalopram was administered. The wash-out period was 3 weeks between the treatments.
RESULTS: Cimetidine (400 mg twice daily) caused a significant increase of 72% in the AUC(0-inf) for escitalopram given as a single oral dose.
A single CYP2D6 poor metabolizer was identified in each of the two studies. However, the results from these subjects were within the ranges of those from the other subjects."
|
| dc:creator | |
| dc:date |
"09/15/2010 13:20:38"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ cimetidine_increases_auc_escitalopram, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1695 }